The modified fusions show to be active as demonstrated by (1) up-regulation of multiple HSPs, MHC class I and class II, CEA, CD80, CD86, CD83, and IL-12; (2) activation of CD4+ and CD8+ T cells able to produce IFN-γ at higher levels; (3) efficient induction of antigen-specific polyclonal CTL activity against tumor targets; and (4) superior abilities to induce CD107+ IFN-γ + CD8+ T cells and CD154+ IFN-γ + CD4+ T cells. The gene discussed is IFNG; the disease is neoplasm.